Mission Therapeutics
Mitophagy is the quality-control process cells harness to remove dysfunctional mitochondria.
Mission specialises in small molecules that enhance mitophagy to inhibit a disease-associated deubiquitylating enzyme (DUB) called USP30 to improve a patient’s cellular health.
Mission’s first-in-class therapeutics also help combat neurodegenerative diseases, including Duchenne muscular dystrophy (DMD), as well as fibrosis, heart and kidney diseases, and rare mitochondria diseases.
In Q1 2024, Mission raised £25.2 million to progress the clinical development of its mitography drug candidates MTX325 and MTX652 for its USP30 program. The investors included Pfizer Venture Investments, Sofinnova Partners, Roche Venture Fund, SR One, IP Group, and Rosetta Capital.
